跳至主要内容
临床试验/NL-OMON34282
NL-OMON34282
已完成
不适用

Two-Center, In-Patient, Randomized, Placebo and Active Comparator Evaluation of the Pharmacokinetics (PK) and Safety, Along with Initial Pharmacodynamic (PD) Efficacy of Three Dose Levels of TBS-2 Intranasal Gel Applied Twice-Daily (BID) for up to Three Days in Female Patients with Hypoactive Sexual Desire Disorder (HSDD) or Anorgasmia (ANOR). - Eval. PK /Safety of TBS-2 Intranasal in Fem. Pat. with HSDD/ANOR

Trimel Biopharma SR0 个研究点目标入组 48 人待定

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Hypoactive Sexual Desire Disorder and Anorgasmia
发起方
Trimel Biopharma SR
入组人数
48
状态
已完成
最后更新
去年

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
去年
研究类型
Interventional

研究者

发起方
Trimel Biopharma SR

入排标准

入选标准

  • Females up to 65 years
  • HSDD with personal distress
  • BMI equal to or less than 35
  • Women must have a score of \>11 on the FSDS\-R

排除标准

  • History of any clinically relevant other psychiatric disorders that could impact sexual function
  • History of Major Depressive Disorder within 6 months prior to study
  • Patients who meet DSM\-IV criteria for Sexual Aversion Disorder, Substance\-Induced Sexual Dysfunction, Dyspareunia (not caused by inadequate foreplay stimulation or alleviated by lubricants), Vaginismus, Gender Identity Disorder, Paraphilia, or for Sexual Dysfunction Due to a General Medical Condition.
  • Patients with pelvic inflammatory disease, urinary tract or vaginal infection

结局指标

主要结局

未指定

相似试验